CR20230200A - Moduladores del regulador de la conductancia transmembrana de la fibrosis quística - Google Patents
Moduladores del regulador de la conductancia transmembrana de la fibrosis quísticaInfo
- Publication number
- CR20230200A CR20230200A CR20230200A CR20230200A CR20230200A CR 20230200 A CR20230200 A CR 20230200A CR 20230200 A CR20230200 A CR 20230200A CR 20230200 A CR20230200 A CR 20230200A CR 20230200 A CR20230200 A CR 20230200A
- Authority
- CR
- Costa Rica
- Prior art keywords
- modulators
- cystic fibrosis
- conductance regulator
- transmembrane conductance
- fibrosis transmembrane
- Prior art date
Links
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 title abstract 4
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Esta descripción proporciona moduladores del regulador de la conductancia transmembrana de la fibrosis quística (CFTR) que tiene la estructura central: composiciones farmacéuticas que contienen al menos un modulador de este tipo, métodos de tratamiento de enfermedades mediadas por CFTR, que incluyen fibrosis quística, mediante el uso de tales moduladores y composiciones farmacéuticas, composiciones farmacéuticas combinadas y terapias combinadas, y procesos y productos intermediarios para la fabricación de tales moduladores.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063088935P | 2020-10-07 | 2020-10-07 | |
PCT/US2021/053860 WO2022076624A1 (en) | 2020-10-07 | 2021-10-06 | Modulators of cystic fibrosis transmembrane conductance regulator |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20230200A true CR20230200A (es) | 2023-07-13 |
Family
ID=78771139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20230200A CR20230200A (es) | 2020-10-07 | 2021-10-06 | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
Country Status (20)
Country | Link |
---|---|
US (1) | US20230382925A1 (es) |
EP (1) | EP4225764A1 (es) |
JP (1) | JP2023545081A (es) |
KR (1) | KR20230104618A (es) |
CN (1) | CN116783204A (es) |
AR (1) | AR123709A1 (es) |
AU (1) | AU2021358063A1 (es) |
BR (1) | BR112023006381A2 (es) |
CA (1) | CA3197857A1 (es) |
CL (1) | CL2023000984A1 (es) |
CO (1) | CO2023005734A2 (es) |
CR (1) | CR20230200A (es) |
DO (1) | DOP2023000066A (es) |
EC (1) | ECSP23032164A (es) |
IL (1) | IL301755A (es) |
MX (1) | MX2023004074A (es) |
PE (1) | PE20231185A1 (es) |
TW (1) | TW202233635A (es) |
UY (1) | UY39460A (es) |
WO (1) | WO2022076624A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023150236A1 (en) | 2022-02-03 | 2023-08-10 | Vertex Pharmaceuticals Incorporated | Methods of preparing and crystalline forms of (6a,12a)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol |
WO2023150237A1 (en) | 2022-02-03 | 2023-08-10 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
WO2023196429A1 (en) * | 2022-04-06 | 2023-10-12 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2023224931A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
WO2024056779A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Crystalline form of (3s,7s,10r,13r)-13-benzyl-20-fluoro-7-isobutyl-n-(2-(3-methoxy-1,2,4-oxadiazol-5-yl)ethyl)-6,9-dimethyl-1,5,8,11-tetraoxo-10-(2,2,2-trifluoroethyl)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-tetradecahydro-[1]oxa[4,7,10,14]tetraazacycloheptadecino[16,17-f]quinoline-3-carboxamide |
WO2024056798A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Macrocyclic cftr modulators |
WO2024056791A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiators |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
LT2489659T (lt) | 2004-06-24 | 2018-03-26 | Vertex Pharmaceuticals Incorporated | Atp rišančios kasetės transporterių moduliatoriai |
SI2404919T1 (sl) | 2005-11-08 | 2013-12-31 | Vertex Pharmaceuticals Incorporated | Heterocikliäśna spojina uporabna kot modulator za prenaĺ alce z atp-vezavno kaseto |
RS60205B1 (sr) | 2005-12-28 | 2020-06-30 | Vertex Pharma | Farmaceutske kompozicije amorfnog oblika n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
JP2009536969A (ja) | 2006-05-12 | 2009-10-22 | バーテックス ファーマシューティカルズ インコーポレイテッド | N−[2,4−ビス(1,1−ジメチルエチル)−5−ヒドロキシフェニル]−1,4−ジヒドロ−4−オキソキノリン−3−カルボキサミド組成物 |
CA2706920C (en) | 2007-12-07 | 2018-02-13 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
PT2639222T (pt) | 2007-12-07 | 2016-11-01 | Vertex Pharma | Processo de produção de ácidos cicloalquilcarboxamido-piridina-benzoicos |
RS56894B1 (sr) | 2008-08-13 | 2018-04-30 | Vertex Pharma | Farmaceutska kompozicija n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida i njeno ordiniranje |
CN102164587A (zh) | 2008-09-29 | 2011-08-24 | 沃泰克斯药物股份有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的剂量单元 |
WO2010053471A1 (en) | 2008-11-06 | 2010-05-14 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
KR101955863B1 (ko) | 2009-03-20 | 2019-03-07 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법 |
NZ700556A (en) | 2010-03-25 | 2016-04-29 | Vertex Pharma | Solid forms of (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide |
WO2011127421A1 (en) | 2010-04-09 | 2011-10-13 | Berkeley Bionics | Exoskeleton load handling system and method of use |
SG10201505700QA (en) | 2010-04-22 | 2015-08-28 | Vertex Pharma | Process of producing cycloalkylcarboxamido-indole compounds |
CA2796642A1 (en) | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
WO2012027731A2 (en) | 2010-08-27 | 2012-03-01 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
HUE032771T2 (en) | 2011-05-18 | 2017-10-30 | Concert Pharmaceuticals Inc | Deuterated ivacaftor derivatives |
HUE047354T2 (hu) | 2011-05-18 | 2020-04-28 | Vertex Pharmaceuticals Europe Ltd | Ivacaftor deuterizált származékai |
NZ629199A (en) | 2012-02-27 | 2017-01-27 | Vertex Pharma | Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
US9012496B2 (en) | 2012-07-16 | 2015-04-21 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof |
RS57831B2 (sr) | 2012-11-02 | 2024-02-29 | Vertex Pharma | Farmaceutske kompozicije za lečenje bolesti posredovanih sa cftr |
WO2014078842A1 (en) | 2012-11-19 | 2014-05-22 | Concert Pharmaceuticals, Inc. | Deuterated cftr potentiators |
SI3131582T1 (sl) | 2014-04-15 | 2018-09-28 | Vertex Pharmaceuticals Incorporated | Farmacevtski sestavki za zdravljenje bolezni, pri katerih posreduje regulator transmembranske prevodnosti |
AU2016326441B2 (en) | 2015-09-21 | 2021-11-25 | Vertex Pharmaceuticals (Europe) Limited | Administration of deuterated CFTR potentiators |
WO2018080591A1 (en) | 2016-10-27 | 2018-05-03 | Vertex Pharmaceuticals (Europe) Limited | Methods of treatment with deuterated cftr potentiators |
PT3752510T (pt) * | 2018-02-15 | 2023-03-15 | Vertex Pharma | Macrociclos como moduladores do regulador de condutância de transmembrana da fibrose cística, suas composições farmacêuticas, seu uso no tratamento da fibrose cística e processos para produzi-los |
TW202102482A (zh) * | 2019-04-03 | 2021-01-16 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白調節劑 |
EP4013760A1 (en) * | 2019-08-14 | 2022-06-22 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
-
2021
- 2021-10-06 AU AU2021358063A patent/AU2021358063A1/en active Pending
- 2021-10-06 US US18/030,529 patent/US20230382925A1/en active Pending
- 2021-10-06 EP EP21814947.4A patent/EP4225764A1/en active Pending
- 2021-10-06 CA CA3197857A patent/CA3197857A1/en active Pending
- 2021-10-06 TW TW110137149A patent/TW202233635A/zh unknown
- 2021-10-06 PE PE2023001369A patent/PE20231185A1/es unknown
- 2021-10-06 JP JP2023521521A patent/JP2023545081A/ja active Pending
- 2021-10-06 WO PCT/US2021/053860 patent/WO2022076624A1/en active Application Filing
- 2021-10-06 IL IL301755A patent/IL301755A/en unknown
- 2021-10-06 CR CR20230200A patent/CR20230200A/es unknown
- 2021-10-06 BR BR112023006381A patent/BR112023006381A2/pt unknown
- 2021-10-06 MX MX2023004074A patent/MX2023004074A/es unknown
- 2021-10-06 KR KR1020237015298A patent/KR20230104618A/ko unknown
- 2021-10-06 CN CN202180081900.1A patent/CN116783204A/zh active Pending
- 2021-10-07 AR ARP210102779A patent/AR123709A1/es unknown
- 2021-10-07 UY UY0001039460A patent/UY39460A/es unknown
-
2023
- 2023-04-05 DO DO2023000066A patent/DOP2023000066A/es unknown
- 2023-04-05 CL CL2023000984A patent/CL2023000984A1/es unknown
- 2023-05-02 EC ECSENADI202332164A patent/ECSP23032164A/es unknown
- 2023-05-05 CO CONC2023/0005734A patent/CO2023005734A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW202233635A (zh) | 2022-09-01 |
AU2021358063A1 (en) | 2023-05-18 |
WO2022076624A1 (en) | 2022-04-14 |
US20230382925A1 (en) | 2023-11-30 |
CL2023000984A1 (es) | 2023-11-24 |
IL301755A (en) | 2023-05-01 |
DOP2023000066A (es) | 2023-07-09 |
AR123709A1 (es) | 2023-01-04 |
UY39460A (es) | 2022-05-31 |
CO2023005734A2 (es) | 2023-07-21 |
CN116783204A (zh) | 2023-09-19 |
BR112023006381A2 (pt) | 2023-09-26 |
CA3197857A1 (en) | 2022-04-14 |
ECSP23032164A (es) | 2023-06-30 |
JP2023545081A (ja) | 2023-10-26 |
KR20230104618A (ko) | 2023-07-10 |
EP4225764A1 (en) | 2023-08-16 |
PE20231185A1 (es) | 2023-08-11 |
MX2023004074A (es) | 2023-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP23032164A (es) | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística | |
CO2023005736A2 (es) | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística | |
CO2022002749A2 (es) | Moduladores del regulador de conductancia transmembrana de la fibrosis quística | |
ECSP23032843A (es) | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística | |
UY39374A (es) | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística | |
UY39723A (es) | Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador | |
UY37617A (es) | Moduladores de la proteína reguladora de la conductancia transmembrana en fibrosis quística y métodos de empleo | |
UY39458A (es) | Moduladores del regulador de conductancia transmembranario de la fibrosis quística | |
UY39455A (es) | Moduladores del regulador de conductancia transmembranario de la fibrosis quística | |
DOP2022000091A (es) | Degradadores de moléculas pequeñas de helios y procedimientos de uso | |
CO2022007814A2 (es) | Ligandos de la pseudoquinasa tyk2 | |
CL2021002078A1 (es) | Composiciones y métodos para la administración de polipéptidos cftr. | |
BR112021019102A2 (pt) | Composições e métodos para tratamento de fibrose cística | |
BR112016029926A2 (pt) | administração nasal | |
UY39521A (es) | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística | |
UY39603A (es) | Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso | |
ECSP20082568A (es) | Métodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropión |